2023
HRD signature and HRD genomic landscape of tumors from 896 patients with early-stage breast cancer (BC).
Jeon J, Chen K, Madison R, Schrock A, Sokol E, Levy M, Oxnard G, Huang R, Pusztai L. HRD signature and HRD genomic landscape of tumors from 896 patients with early-stage breast cancer (BC). Journal Of Clinical Oncology 2023, 41: 539-539. DOI: 10.1200/jco.2023.41.16_suppl.539.Peer-Reviewed Original ResearchEarly-stage breast cancerPrimary breast cancerEarly breast cancerBreast cancerStage IHR-/HER2HRR deficiencyPALB2 mutationsEarly-stage primary breast cancerPARP inhibitorsStage IV diseaseHormone receptor statusMonths of diagnosisPositive breast cancerHomologous recombination repairComprehensive genomic profilingHRD signaturesClinical trial dataHigh rateSEER studySomatic BRCAAdjuvant therapyAdvanced diseaseReceptor statusBC subtypes
2022
The mutational profile of ER-, PR+, HER2- metastatic breast cancer.
Fischbach N, Huang R, Lustberg M, Pelletier M, Pusztai L, Sivakumar S, Sokol E, Ross J, Levy M. The mutational profile of ER-, PR+, HER2- metastatic breast cancer. Journal Of Clinical Oncology 2022, 40: 1025-1025. DOI: 10.1200/jco.2022.40.16_suppl.1025.Peer-Reviewed Original ResearchTriple-negative breast cancerComprehensive genomic profilingMetastatic breast cancerBreast cancerClinical trialsPathology reportsMutational profileHER2- metastatic breast cancerConsecutive breast cancersAnti-estrogen therapyNegative breast cancerPD-L1 IHCPotential therapeutic implicationsHigh rateEndocrine therapyEstrogen therapyPatient ageFoundation MedicineKRAS alterationsRare subtypeHER2 expressionClinical behaviorReceptor phenotypeBreast carcinomaTreatment strategies
2018
Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Powles RL, Redmond D, Sotiriou C, Loi S, Fumagalli D, Nuciforo P, Harbeck N, de Azambuja E, Sarp S, Di Cosimo S, Huober J, Baselga J, Piccart-Gebhart M, Elemento O, Pusztai L, Hatzis C. Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncology 2018, 4: e181564-e181564. PMID: 29902299, PMCID: PMC6224305, DOI: 10.1001/jamaoncol.2018.1564.Peer-Reviewed Original ResearchConceptsDual HER2 blockadeImmune gene signaturesPathologic complete responseDual HER2HER2 blockadeNeoALTTO trialDual anti-HER2 blockadeHigher immune gene expressionTrastuzumab Treatment Optimisation (ALTTO) trialHER2-positive breast cancerGene signatureAnti-HER2 blockadeHigher useHER2-positive patientsMultivariable logistic regressionRandomized clinical trialsGood responseHigh rateImmune gene expressionNeoadjuvant lapatinibTherapy armIdentifies patientsNeoadjuvant therapyComplete responseGene expression signatures
2012
Distinct tumor protein p53 mutants in breast cancer subgroups
Dumay A, Feugeas J, Wittmer E, Lehmann‐Che J, Bertheau P, Espié M, Plassa L, Cottu P, Marty M, André F, Sotiriou C, Pusztai L, de Thé H. Distinct tumor protein p53 mutants in breast cancer subgroups. International Journal Of Cancer 2012, 132: 1227-1231. PMID: 22886769, DOI: 10.1002/ijc.27767.Peer-Reviewed Original ResearchConceptsBasal tumorsLuminal tumorsMolecular apocrine tumoursDifferent breast cancer subtypesBreast cancer subgroupsBreast cancer subtypesP53 mutation statusApocrine tumorsTumor protein p53Molecular apocrineCancer subgroupsBreast cancerTP53 alterationsMutation statusBreast tumorsLoss of functionCancer subtypesTumorsComplex mutationsP53 gainHigh frequencyHigh rateDifferent functional consequencesMissense mutationsProtein p53
2011
P2-02-09: TP53 Mutation Patterns in Breast Cancer Subgroups.
Dumay A, Feugeas J, Wittmer E, Lehmann-Che J, Bertheau P, Espié M, de C, André F, Sotiriou C, Pusztai L, de T. P2-02-09: TP53 Mutation Patterns in Breast Cancer Subgroups. Cancer Research 2011, 71: p2-02-09-p2-02-09. DOI: 10.1158/0008-5472.sabcs11-p2-02-09.Peer-Reviewed Original ResearchLuminal tumorsMolecular apocrineBreast cancerTP53 mutationsDifferent molecular subclassesLuminal B subgroupMolecular apocrine tumoursTruncating mutationsBreast cancer subgroupsBreast cancer subclassesTP53 mutation frequencyFunctional assaysMutation typeTP53 mutation patternsHigh rateTumor protein 53Missense mutationsApocrine tumorsBasal tumorsLuminal subgroupCancer subgroupsP53 gene inactivationMolecular subclassesBreast tumorsSpecific subtypes
2003
Estrogen Receptors and Distinct Patterns of Breast Cancer Relapse
Hess KR, Pusztai L, Buzdar AU, Hortobagyi GN. Estrogen Receptors and Distinct Patterns of Breast Cancer Relapse. Breast Cancer Research And Treatment 2003, 78: 105-118. PMID: 12611463, DOI: 10.1023/a:1022166517963.Peer-Reviewed Original ResearchConceptsER-negative statusER-positive tumorsSite of recurrenceBreast cancer deathsFirst recurrenceER statusTumor recurrenceCancer deathClinical behaviorAdjuvant therapy protocolsOperable stage IIER-negative cancersER-positive statusRate of recurrenceBreast cancer relapseHigh rateMenopausal statusTumor burdenRecurrence rateBreast cancerEstrogen receptorCancer relapseRecurrencePatientsStage II